Shares of Bayer Aktiengesellschaft (OTCMKTS: BAYRY) experienced a notable decline of 4.9% during trading on Friday, reaching a low of $8.1250 before closing at $8.18. This downturn occurred amid a significant drop in trading volume, with 227,172 shares exchanged, representing a 68% decrease from the average session volume of 710,827 shares. The stock had previously closed at $8.60.
Analysts Adjust Ratings for Bayer Aktiengesellschaft
Several research analysts have recently issued updates regarding Bayer’s stock. On August 19, 2023, Wall Street Zen upgraded Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating. Conversely, Zacks Research downgraded the stock from a “strong-buy” to a “hold” rating on November 3, 2023. Currently, the consensus rating for Bayer Aktiengesellschaft is “Buy,” with two analysts rating the stock as a Strong Buy, one as Buy, and another as Hold, according to data from MarketBeat.
Bayer operates globally as a life science company, providing various products across its three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment focuses on prescription products for cardiology and women’s health, along with specialty therapeutics in oncology, hematology, and ophthalmology. Additionally, it offers diagnostic imaging equipment, digital solutions, and contrast agents, as well as advancements in cell and gene therapy.
As the market responds to these rating adjustments, investors and analysts alike will be keenly observing Bayer’s stock performance in the coming days.
